2015
Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer
Kwon Y, Han C, Yu J, Kim S, Modi P, Davis R, Park J, Lee P, Ha Y, Kim W, Kim I. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clinical Genitourinary Cancer 2015, 14: e1-e8. PMID: 26341038, PMCID: PMC5767465, DOI: 10.1016/j.clgc.2015.07.018.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerAbsolute lymphocyte countAbsolute neutrophil countLow-risk prostate cancer patientsProstate cancer patientsProstate cancerLymphocyte countANC groupLymphocyte ratioBiochemical recurrenceCancer patientsActive surveillanceHigher prostate-specific antigen levelMetastatic castration-resistant prostate cancerLow-risk PCa patientsProstate-specific antigen levelHigh absolute lymphocyte countCastration-resistant prostate cancerBiochemical recurrence-free survivalRobot-assisted radical prostatectomyAdverse pathologic outcomesAppropriate patient selectionKaplan-Meier methodRecurrence-free survivalRisk stratification tool
2012
Ras Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer
Kim J, Chae Y, Ha Y, Kim I, Byun S, Yun S, Kim W. Ras Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer. Clinical Genitourinary Cancer 2012, 10: 114-120. PMID: 22382007, DOI: 10.1016/j.clgc.2011.12.003.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Transitional CellChildDNA MethylationFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPrognosisPromoter Regions, GeneticProportional Hazards ModelsTumor BurdenTumor Suppressor ProteinsUrinary Bladder NeoplasmsYoung AdultConceptsRecurrent nonmuscle invasive bladder cancerNonmuscle invasive bladder cancerMuscle-invasive bladder cancerInvasive bladder cancerPrimary BC tissuesCox regression analysisBladder cancerPrognostic markerRASSF1A methylationRASSF1A hypermethylationIndependent predictorsBC tissuesMultivariate Cox regression analysisCancer progressionKaplan-Meier analysisAdvanced tumor stagePromising prognostic markerPromoter hypermethylationPotential prognostic markerRegression analysisRASSF1A promoter hypermethylationMethylation-specific polymerase chain reactionClinicopathologic featuresPrognostic significanceKaplan-Meier
2010
HMOX1 is an Important Prognostic Indicator of Nonmuscle Invasive Bladder Cancer Recurrence and Progression
Yim M, Ha Y, Kim I, Yun S, Choi Y, Kim W. HMOX1 is an Important Prognostic Indicator of Nonmuscle Invasive Bladder Cancer Recurrence and Progression. Journal Of Urology 2010, 185: 701-705. PMID: 21168882, DOI: 10.1016/j.juro.2010.09.081.Peer-Reviewed Original ResearchAgedBiomarkers, TumorBiopsy, NeedleCarcinoma, Transitional CellCohort StudiesCystectomyDisease ProgressionFemaleGene Expression Regulation, NeoplasticHeme Oxygenase-1HumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm Recurrence, LocalPrognosisProportional Hazards ModelsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSensitivity and SpecificitySurvival AnalysisUrinary Bladder NeoplasmsAnalysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: A novel approach using peptide nucleic acid-mediated, real-time PCR clamping
Kim E, Yan C, Ha Y, Jeong P, Kim I, Moon S, Choi Y, Kim W. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: A novel approach using peptide nucleic acid-mediated, real-time PCR clamping. Urologic Oncology Seminars And Original Investigations 2010, 30: 673-679. PMID: 20884250, DOI: 10.1016/j.urolonc.2010.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorDNA GlycosylasesFemaleGene FrequencyGenotypeHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMusclesNeoplasm GradingNeoplasm InvasivenessNeoplasm StagingPeptide Nucleic AcidsPolymerase Chain ReactionPolymorphism, GeneticPrognosisProportional Hazards ModelsUrinary Bladder NeoplasmsConceptsMuscle-invasive bladder cancerReal-time PCR clampingInvasive bladder cancerBladder cancerHOGG1 genotypeHOGG1 codon 326 genotypesMultivariate Cox regression analysisHOGG1 codon 326Cancer-specific survivalCox regression analysisPrognostic genetic markersPCR clampingSpecific survivalSurvival benefitClinicopathologic characteristicsBC patientsPrognostic indicatorTumor gradePrognostic markerClinical dataProtective effectCancerPatientsDNA damage repair mechanismsCodon 326
2004
Tissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy
Shariat S, Menesses-Diaz A, Kim I, Muramoto M, Wheeler T, Slawin K. Tissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology 2004, 63: 1191-1197. PMID: 15183988, DOI: 10.1016/j.urology.2003.12.015.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedDisease ProgressionFollow-Up StudiesHumansImmunohistochemistryMaleMiddle AgedMultivariate AnalysisNeoplasm StagingProstateProstatectomyProstate-Specific AntigenProstatic HyperplasiaProstatic NeoplasmsReceptors, Transforming Growth Factor betaTransforming Growth Factor betaTransforming Growth Factor beta1ConceptsPlasma TGF-beta1 levelsTGF-beta1 levelsAbnormal expressionTGFbeta-RIITGFbeta-RIBiochemical progressionRadical prostatectomyProstate cancerPathologic Gleason scoreSeminal vesicle involvementSurgical margin statusProstate cancer featuresTissue expressionGrowth factor-β1TGF-beta1 overexpressionConsecutive patientsExtracapsular diseaseMargin statusPathologic featuresGleason scoreBlood levelsLoss of expressionPrognostic markerImmunohistochemical stainingFactor-β1